Nurix Therapeutics (NRIX) investor relations material

Pipeline and clinical progress

• Lead BTK degrader Bexobrutideg is entering phase III trials for CLL, with ambitions in autoimmune indications as well.

• Reported 83% overall response rate and 22-month PFS in advanced CLL patients, supporting rapid site activation and strong physician interest.

• Confirmatory trial design updated to compare against newly approved pirtobrutinib, aiming for global relevance and competitive positioning.

• Differentiation from competitors highlighted by greater potency, selectivity, and safety, with potential best-in-class profile.

• Additional cohorts include CNS disease, leveraging blood-brain barrier penetration as a unique feature.

Autoimmune and early-stage programs

• New oral formulation for autoimmune use aims to improve absorption and reduce pill burden, with healthy volunteer data expected later this year.

• Indication options span dermatologic, neurologic (e.g., MS), and hematologic autoimmune diseases, with a focus on rapid development timelines.

• STAT6 program with Sanofi is nearing clinical entry, with a 50/50 US co-commercialization option post-proof of concept.

• IRAK4 program with Gilead is in phase I, with data anticipated this year, emphasizing selectivity and safety.

Platform innovation and financials

• Degrader antibody conjugates (DACs) highlighted as a next wave of platform productivity, with ongoing collaboration with Pfizer (formerly Seagen).

• Cash position of approximately $650 million provides operational runway into the second half of 2027, supporting ongoing pivotal trials.

• Anticipated increased data flow and news in the second half of the year as multiple trials progress.